These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8060383)

  • 1. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
    Larsen ML; Illingworth DR; O'Malley JP
    Atherosclerosis; 1994 Apr; 106(2):235-40. PubMed ID: 8060383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
    Illingworth DR; O'Malley JP
    Metabolism; 1990 Apr; 39(4):403-9. PubMed ID: 2182974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
    Hoogwerf BJ; Peters JR; Frantz ID; Hunninghake DB
    Metabolism; 1985 Oct; 34(10):978-81. PubMed ID: 4046841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
    Feussner G; Eichinger M; Ziegler R
    Clin Investig; 1992 Nov; 70(11):1027-35. PubMed ID: 1472833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
    Feussner G; Kurth B; Lohrmann J
    Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipoprotein lipids after gemfibrozil treatment.
    Schwandt P; Weisweiler P; Neureuther G
    Artery; 1979 Feb; 5(2):117-24. PubMed ID: 231950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutritional & pharmacologic management of hyperlipoproteinemia.
    Pickering JE
    Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL; East C; Grundy SM
    Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
    Stuyt PM; Demacker PN; van't Laar A
    Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
    Rabkin SW; Hayden M; Frohlich J
    Atherosclerosis; 1988 Oct; 73(2-3):233-40. PubMed ID: 3056431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol in the plasma very low density lipoprotein fraction in patients with type III hyperlipoproteinemia: analysis of factors which modulate its concentration.
    Sutherland WH; Janus ED; Nye ER; Grant S
    Biochem Med Metab Biol; 1988 Jun; 39(3):305-11. PubMed ID: 3165001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.